Top Clean Energy Companies To Buy For 2014

With shares of Molycorp (NYSE:MCP) trading around $5, is MCP an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Molycorp engages in the production and sale of rare earth products that include oxides, metals, alloys, and magnets for various inputs in existing and emerging applications comprising clean energy technologies, multiple high-tech uses, defense applications, and water treatment technology. The research and exploration of rare earth products has been a hot trend in recent times. If these products to indeed produce significant results, companies like Molycorp stand to see explosive growth. As these technologies continue to be developed, look for Molycorp to make enormous profits if they become mainstream.

T = Technicals on the Stock Chart are Weak

Molycorp stock has witnessed a fair amount of selling pressure that has taken it to relatively low prices. The stock seems to be stabilizing at these prices but there does not seem to be an indication of a trend. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Molycorp is trading slightly below its key averages which signal neutral to bearish price action in the near-term.

Best Gas Stocks To Invest In Right Now: Idera Pharmaceuticals Inc.(IDRA)

Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer?s disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  In trading on Tuesday, healthcare shares were relative leaders, up on the day by about 1.50 percent. Meanwhile, top gainers in the sector included Allergan (NYSE: AGN), up 15.7 percent, and Idera Pharmaceuticals (NASDAQ: IDRA), up 16.5 percent. Non-cyclical consumer goods & services shares dropped around 0.05 percent in today's trading.

• [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

  Idera Pharmaceuticals Inc.(IDRA) said a recent clinical study of its plaque psoriasis treatment met its objectives, allowing the company to push forward with the treatment’s development. The company’s shares jumped 32% to $5.14 premarket.

• [By Dan Caplinger]

  Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more encouraging assessment of how long interest rates might remain low in order to stimulate and sustain economic growth, stocks climbed sharply, with the Dow posting triple-digit gains. Yet for MannKind (NASDAQ: MNKD  ) , Momenta Pharmaceuticals (NASDAQ: MNTA  ) , and Idera Pharmaceuticals (NASDAQ: IDRA  ) , the news today was far from good, as all three stocks suffered declines of 10% or more.

• [By John Udovich]
  Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:

  ��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>

Top Clean Energy Companies To Buy For 2014: Tata Motors Ltd(TTM)

Tata Motors Limited, an automobile company, engages in the manufacture and sale of commercial and passenger vehicles primarily in India. The company offers cars, utility vehicles, trucks, buses and coaches, and defense vehicles, as well as develops electric and hybrid vehicles for personal and public transportation. It also involves in distributing and marketing cars; and financing the vehicles sold by the company. In addition, the company engages in the provision of engineering and automotive solutions, as well as machine tools and factory automation solutions; construction equipment manufacturing; automotive vehicle components manufacturing and supply chain activities; tooling and plastic and electronic components for automotive and computer applications; and automotive retailing and service operations. It offers its products and services through its dealership, sales, services, and spare parts network. The company also markets its commercial and passenger vehicles in Eu rope, Africa, the Middle East, South East Asia, South Asia, and South America. The company was formerly known as Tata Engineering and Locomotive Company Limited and changed its name to Tata Motors Limited in July 2003. Tata Motors Limited was founded in 1945 and is based in Mumbai, India.

Advisors' Opinion:

• [By Justin Loiseau]

  2. Gimme those car keys
  Sniff ... they grow up so fast. Before we know it, little Georgie's going to be ready to sit his royal tuckus in the driver seat. Tata Motors (NYSE: TTM  ) offers a flashback to the days of British colonialism, although this time it's India with the ownership. Although the South Asian automaker is most famous for its Tata Nano, the world's cheapest car, Prince George would probably have his eyes set on Tata's Jaguar Land Rover subsidiary.

• [By John Rosevear]

  Ever since India's Tata Motors (NYSE: TTM  ) bought Jaguar and Land Rover from Ford (NYSE: F  ) in 2008, one big question has been asked: Would Tata be willing (and able) to make the big investments needed to make Jaguar a competitive global luxury brand?

Top Clean Energy Companies To Buy For 2014: Spdr S&P Retail Etf (XRT)

SPDR S&P Retail Exchange Traded Fund (The Fund) seeks to replicate as closely as possible, before expenses, the performance of an index derived from the retail segment of the United States total market composite index. The Fund uses a passive management strategy designed to track the total return performance of the S&P Retail Select Industry Index (the Retail Index).

The Retail Index represents the retail sub industry portion of the S&P TMI. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange (NYSE), American Stock Exchange (AMEX), National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Advisors' Opinion:

• [By Don Lucek]

  It's a well-run affair that beat the S&P 500 (SPX) and the S&P Retail (XRT) over the recent past. While I'd be careful about entry, I think GPS will remain a stock market winner into the longer term (at least one to three years).

• [By Ben Levisohn]

  Shares of J.C. Penney have dropped 2.5% to $13.48 today, while Vornado has fallen 1.7% to $81.44. The SPDR S&P 500 ETF (SPY) has fallen 0.4% to $165.75, and the SPDR S&P Retail ETF (XRT) is of 0.8% at $79.42.

• [By John Udovich]

  Small cap apparel and accessories retailer The Jones Group Inc (NYSE: JNY) has been rising on speculation of a buyout, but the stock has also underperformed the both the SPDR S&P Retail ETF (NYSEARCA: XRT) and the Dow over the longer haul. Nevertheless, the buyout speculation does make the stock worthy of a closer look.

• [By John Udovich]

  Small cap storage and organization system retailer Container Store Group Inc (NYSE: TCS) is the latest hot consumer IPO to�temp�investors�and while there are no direct peers for the quirky but money loosing retailer, could investors just�be better off sticking with retail ETFs like the SPDR S&P Retail ETF (NYSEARCA: XRT) or�more traditional large cap home improvement stocks like�Lowe's Companies, Inc (NYSE: LOW) and The Home Depot, Inc (NYSE: HD)?

Top Clean Energy Companies To Buy For 2014: SPDR EURO STOXX 50 ETF (FEZ)

SPDR DJ Euro Stoxx 50 ETF (the Fund), formerly DJ Euro Stoxx 50 ETF, seeks to replicate as closely as possible the price and yield of the Dow Jones EURO STOXX 50 Index (the Index). The Index seeks to provide a blue-chip representation of the market sector leaders in the Eurozone. The Index represents the performance of the 50 largest companies within the Eurozone portion of the Dow Jones STOXX Total Market Index. The Index is a free-float market capitalization weighted index that captures approximately 60% of the underlying market and covers approximately 95% of the free-float market capitalization of the investable universe in the Eurozone.

The Fund utilizes a passive or indexing approach to invest in a portfolio of stocks to replicate the Index. The Fund�� investment advisor is SSgA Funds Management, Inc.

Advisors' Opinion:

• [By Chris Ciovacco]

  In Thursday's ETF analysis, evidence is presented that supports increasing demand for assets that get a tailwind from a weak U.S. dollar, including emerging markets (EEM) and foreign stocks (EFA). Casting a wider economic net, our market model told us to start buying stocks last week even with the threat of a U.S. default. Wednesday, we continued with our incremental allocation shifts by adding some exposure to the energy sector. Thursday, we sat tight holding long positions in small caps (IJR), Europe (FEZ), emerging markets and technology (QQQ). The upper bounds of the bullish S&P 500 trend channel shown below may offer some resistance to the market's near vertical ascent.

• [By Tom Aspray]

  The news out of the Eurozone continues to improve as their Purchasing Managers Index rose to 51.7 in August consistent with an expanding economy. The chart shows a nice trend here suggesting that the worst by indeed be over. A deeper pullback in some of the euro ETFs like SPDR Euro STOXX 50 ETF (FEZ) should create a buying opportunity.